The FDA handed down a major shock to AstraZeneca yesterday when it rejected its key hyperkalemia drug ZS-9, leaving potential rival Relypsa’s shares to jump in…

Clinicians looking for a reliable, controlled method to treat a host of recovering opioid addicts will now have a new resource in the armamentarium.

A few weeks after the FDA slapped a clinical hold on GlaxoSmithKline’s late-stage work on an experimental drug for a rare cardiac condition, the pharma giant…

A trio of Israeli biotechs have completed the initial filings for IPOs to raise up to $130 million each--but are holding off until demand picks up.

A startup has picked up a Merck Serono castoff, signed up the R&D chief who axed the drug and set about turning it into a multiple myeloma combo treatment.

The FDA’s diabetes experts provided their second endorsement for a treatment duo in two days, voting 12 to 2 to back Sanofi’s marketing application.

Circassia has initiated an adaptive-design Phase III trial of its grass allergy immunotherapy, setting it up to deliver data in 2018.

Galapagos and Gilead will give 200-mg doses of filgotinib in their upcoming Phase III trial, quashing concerns that testicular toxicity would limit dosing.